Zsuzsanna Kurti

Zsuzsanna Kurti

Auto-generated profile, based on publicly available information

Zsuzsanna Kurti

Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
FRFanni Rencz
Fanni Rencz
Peter L LakatosPeter L Lakatos
Peter L Lakatos
LGLászló Gulácsi
László Gulácsi
VBValentin Brodszky
Valentin Brodszky
ZKZsuzsanna Kürti
Zsuzsanna Kürti
KPKároly Palatka
Károly Palatka

16 May 2014 in The European Journal of Health Economics
Verified
Journal Article
Closed access
PDF file
MMMandel D. Michael
Mandel D. Michael
ABAnita Bálint
Anita Bálint
BLBarbara D. Lovász
Barbara D. Lovász
LGLászló Gulácsi
László Gulácsi
BSBálint Strbák
Bálint Strbák
Peter L LakatosPeter L Lakatos
Peter L Lakatos

21 June 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
PGPetra A Golovics
Petra A Golovics
LLLaszlo Lakatos
Laszlo Lakatos
MMMichael D Mandel
Michael D Mandel
BLBarbara D Lovasz
Barbara D Lovasz
ZVZsuzsanna Vegh
Zsuzsanna Vegh
Peter L LakatosPeter L Lakatos
Peter L Lakatos
AIM: To analyze the prevalence, length and predictors of hospitalization in the biological era in the population-based inception cohort from Veszprem province. METHODS: Data of 331 incident Crohn’s disease (CD) patients diagnosed between January 1, 2000 and December 31, 2010 were analyzed (median age at diagnosis: 28; IQR: 21-40 years). Both in- and outpatient records were collected and comprehensively reviewed. RESULTS: Probabilities of first CD-related hospitalization and re-hospitalization were 32.3%, 45.5%, 53.7% and 13.6%, 23.9%, 29.8%, respectively after one, three and five years of follow-up in Kaplan-Meier analysis. First-year hospitalizations were related to diagnostic procedures (37%), surgery or disease activity (27% and 21%). Non-inflammatory disease behavior at diagnosis (HR = 1.32, P = 0.001) and perianal disease (HR = 1.47, P = 0.04) were associated with time to first CD-related hospitalization, while disease behavior change (HR = 2.38, P = 0.002) and need for steroids (HR = 3.14, P = 0.003) were associated with time to first re-hospitalization in multivariate analyses. Early CD-related hospitalization (within the year of diagnosis) was independently associated with need for immunosuppressives (OR = 2.08, P = 0.001) and need for surgeries (OR = 7.25, P < 0.001) during the disease course. CONCLUSION: Hospitalization and re-hospitalization rates are still high in this cohort, especially during the first-year after the diagnosis. Non-inflammatory disease behavior at diagnosis was identified as the pivotal predictive factor of both hospitalization and re-hospitalization.

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
ZKZsuzsanna Kurti
Zsuzsanna Kurti
BLBarbara D Lovasz
Barbara D Lovasz
MMMichael D Mandel
Michael D Mandel
ZCZoltan Csima
Zoltan Csima
PGPetra A Golovics
Petra A Golovics
Peter L LakatosPeter L Lakatos
Peter L Lakatos
AIM: To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection (CDI). METHODS: A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May 2013. Two hundred and forty-seven inpatients were prospectively diagnosed with CDI. For the risk analysis a 1:3 matching was used. Data of 732 patients matched for age, sex, and inpatient care period and unit were compared to those of the CDI population. Inpatient records were collected from an electronic hospital database and comprehensively reviewed. RESULTS: Incidence of CDI was 21.0/1000 admissions (2.1% of all-cause hospitalizations and 4.45% of total inpatient days). The incidence of severe CDI was 12.6% (2.63/1000 of all-cause hospitalizations). Distribution of CDI cases was different according to the unit type, with highest incidence rates in hematology, gastroenterology and nephrology units (32.9, 25 and 24.6/1000 admissions, respectively) and lowest rates in 1.4% (33/2312) in endocrinology and general internal medicine (14.2 and 16.9/1000 admissions) units. Recurrence of CDI was 11.3% within 12 wk after discharge. Duration of hospital stay was longer in patients with CDI compared to controls (17.6 ± 10.8 d vs 12.4 ± 7.71 d). CDI accounted for 6.3% of all-inpatient deaths, and 30-d mortality rate was 21.9% (54/247 cases). Risk factors for CDI were antibiotic therapy [including third-generation cephalosporins or fluoroquinolones, odds ratio (OR) = 4.559; P < 0.001], use of proton pump inhibitors (OR = 2.082, P < 0.001), previous hospitalization within 12 mo (OR = 3.167, P < 0.001), previous CDI (OR = 15.32; P < 0.001), while presence of diabetes mellitus was associated with a decreased risk for CDI (OR = 0.484; P < 0.001). Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination (P < 0.001), and antibiotic therapy duration was longer (P < 0.02). Severity, mortality and outcome of primary infections and relapsing cases did not significantly differ. CONCLUSION: CDI was accounted for significant burden with longer hospitalization and adverse outcomes. Antibiotic, PPI therapy and previous hospitalization or CDI were risk factors for CDI.

8 August 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
LGLorant Gonczi
Lorant Gonczi
ZKZsuzsanna Kurti
Zsuzsanna Kurti
MRMariann Rutka
Mariann Rutka
ZVZsuzsanna Vegh
Zsuzsanna Vegh
KFKlaudia Farkas
Klaudia Farkas
Peter L LakatosPeter L Lakatos
Peter L Lakatos
Therapeutic drug monitoring (TDM) aid therapeutic decision making in patients with inflammatory bowel disease (IBD) who lose response to anti-TNF therapy. Our aim was to evaluate the frequency and predictive factors of loss of response (LOR) to adalimumab using TDM in IBD patients. One hundred twelve IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62, mean age CD/UC: 36/35 years) were enrolled in this consecutive cohort from two referral centres in Hungary. Demographic data were comprehensively collected and harmonized monitoring strategy was applied. Previous and current therapy, laboratory data and clinical activity were recorded at the time of TDM. Patients were evaluated either at the time of suspected LOR or during follow-up. TDM measurements were determined by commercial ELISA (LISA TRACKER, Theradiag, France). Among 112 IBD patients, LOR/drug persistence was 25.9%/74.1%. The cumulative ADA positivity (>10 ng/mL) and low TL (<5.0 μg/mL) was 12.1% and 17.8% after 1 year and 17.3% and 29.5% after 2 years of adalimumab therapy. Dose intensification was needed in 29.5% of the patients. Female gender and ADA positivity were associated with LOR (female gender: p < 0.001, OR:7.8 CI 95%: 2.5–24.3, ADA positivity: p = 0.007 OR:3.6 CI 95%: 1.4–9.5). ADA development, low TL and need for dose intensification were frequent during adalimumab therapy and support the selective use of TDM in IBD patients treated with adalimumab. ADA positivity and gender were predictors of LOR.

14 October 2014 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
ZVZsuzsanna Vegh
Zsuzsanna Vegh
PGPetra Anna Golovics
Petra Anna Golovics
BLBarbara Dorottya Lovasz
Barbara Dorottya Lovasz
ZKZsuzsanna Kurti
Zsuzsanna Kurti
KGKrisztina Barbara Gecse
Krisztina Barbara Gecse
Peter L LakatosPeter L Lakatos
Peter L Lakatos
Objective. Patients with inflammatory bowel diseases (IBD) are considered to have an increased risk for venous thromboembolism (VTE). The aim of the present study was to analyze the incidence and risk factors of VTE in a population-based inception cohort in the Veszprem province database between 1977 and 2012. Material and methods. A total of 1708 incepted IBD patients were included (male/female: 879/829; CD (Crohn’s disease): 648, age at onset: 29, interquartile range (IQR): 22–39; UC (ulcerative colitis): 1060, age at onset: 36, IQR: 26–50 years). Both in- and outpatient records were collected and comprehensively reviewed and followed up for a total of 21,369 patient-years. Results. Twenty-two VTE events were identified in 19 patients (6 events in 5 CD and 16 in 14 UC patients). The incidence rate of VTE in IBD was 1.03 per 1000 patient-years. The risk of VTE in UC was associated with extensive location (odds ratio (OR): 3.25, 95% confidence interval (CI): 1.13–9.35), presence of fulminant episode during the disease course (OR: 4.15, 95% CI: 1.28–13.5), smoking (OR: 3.46, 95% CI: 1.14–10.5), and need for steroids (OR: 2.97, 95% CI: 0.99–8.92). Conclusion. The incidence of VTE was lower than previously reported. The incidence was higher in males and in UC it was associated with extensive disease, fulminant episodes, corticosteroids-requiring disease and smoking, but not with age at onset.